The latest announcement is out from AIM ImmunoTech ( (AIM) ).
On September 11, 2024, the compensation committee reduced the cash compensation of CEO Thomas K. Equels from $750,000 to $650,000, compensating the difference with restricted common stock shares valued at $100,000. Additionally, corrections were made to the compensation timelines for Mr. Equels and Mr. Rodino, aligning them with the year ending August 12, 2025. These adjustments and corrections have been formalized in amended employment agreements.
For detailed information about AIM stock, go to TipRanks’ Stock Analysis page.
